arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Mirum Pharmaceuticals, Inc.

MIRM
$100.66 ▲ +6.56 (+6.97%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
34 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
34
Health
Poor
Bearish
auto_awesome

Analytical Summary

Mirum Pharmaceuticals, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $5.9B
Dividend Yield
Revenue Growth 43.3%
Op. Margin -493.8%
ROIC -325.8%
FCF / Share $-3.90
Trailing P/E
Price / Book 25.3x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

34-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$159.88M
↑ +43.3%
Net Income Profit after all expenses
$-790.15M
↓ -5283.6%
Operating Margin Operating profit as % of sales
-493.8%
↓ -16002.4% 21th
FCF / Share Free cash flow per share
$-3.90
↓ -9420.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
35
Returns
36
Financial Health
43
Cash Quality
6

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 34 quarters